You are here

Biologx

BiologX Proprietary Technology Rapidly Produces More Insulin, at up to 70% Less Than Current Prices to the Patient

Your investment will help us quickly bring our Insulin to market.*

 


The Rising Price of Insulin Is Deadly

Biologx Insulin Price Chart

Over the last decade, insulin prices have been controlled and increased by three major pharmaceutical companies, costing some diabetic patients their lives. Insulin is a hormone produced by the pancreas and is critical for the regulation of glucose (sugar) in the blood. Insulin is Insulin, and we firmly believe it should be affordable to those who need it. Invest now to help us save lives.

images

Real Stories From Diabetic Patients

“Boyle died because he was $50 short of reaching his $750 GoFundMe goal to pay for a month's supply of insulin”

– VICE, MAY 2017: The High Price of Insulin is Literally Killing People

“Nobody cared or nobody understood that without this next vial of insulin, I wouldn't live to see another week”

– Kristen Whitney Daniels: CBS NEWS, 2019

“Woman says her son couldn't afford his insulin – now he's dead”

– CBS NEWS: Mother Fights for Lower Insulin Prices After Son's Tragic Death

BiologX Proprietary Insulin Production Can Save Lives

When we set out to make high quality insulin affordable, we worked hard to eliminate inefficiencies throughout the production process. BiologX has devised unique processes for the production of recombinant human insulin (RHI) that enable us to make more insulin in a shorter period of time – all at affordable costs to patients worldwide. Our life-saving insulins meet or exceed USP Reference Standards, the highest quality standards in the market.*

  BiologX Competitors
Product Yield 50% 10-15%
Production Steps 10 30+
Production Time 5-7 days 25-31 days
Overhead Expenses 25% 100%

The Result

BiologX will price our Insulin at up to 70% less than the current market price - because we believe it’s essential to enable easy affordable access to Insulin and because we can make a reasonable profit while doing so.*
*BiologX's insulin product candidate has not yet been approved by the FDA.

full height

Why Invest in BiologX?

Save Lives | Solve Global Problem | Invest for Good
$39B Market Value Global Insulin Market value projections from $27B in 2016
2x Growth Rate Growing at a rate of 2 times the rate of pharma
$4.8B Sales Regular Human Insulin sales expected to exceed $4.8B by 2021
47% Demand Increase Regular Human Insulin sales expected to exceed $4.8B by 2021

Investment Opportunity

logo
BIOLOGX IS “TESTING THE WATERS” UNDER REGULATION A UNDER THE SECURITIES ACT OF 1933. THIS PROCESS ALLOWS COMPANIES TO DETERMINE WHETHER THERE MAY BE INTEREST IN AN OFFERING OF ITS SECURITIES.

Click the "Make Reservation" button to make a non-binding reservation in BiologX, and lock in the initial share price.

If and when the SEC Qualifies the Reg A+ offering, we intend to accept the investments from people with Reservations first. After which, we will immediately change the price of our shares. Please note: SEC regulations do not allow us to inform you what the new price will be, but Regulation A+ allows us to increase the share price by up to 20% without amending our filing with the SEC. We will then re-open the offering at the changed share price for people that did not make a reservation.

Upon SEC Qualification, we will accept investments via Debit Card, Credit Card, ACH, Check, and Wire. We will also accept investments from Self-directed IRA accounts.

  • $4 Price per Share
  • $320 Min. Investment
  • Reg A+ Public Offering

Meet The Team

team member

Ron Zimmerman

Co-Founder & Chief Science Officer

×

Ron Zimmerman

Co-Founder & Chief Science Officer

Ron has extensive experience leading specialty pharmaceutical companies. Prior to founding ZBP, he was the Founder & President of Elona Biotechnologies, Inc., a technology leader in proteomics, process development and characterization of therapeutic proteins. With offices, laboratories and production facilities located south of Indianapolis, the company was involved in the development and production of human insulin, insulin analogs, growth hormones, and other “follow-on” proteins to treat chronic diseases. Ron was also a founding member of the management team that grew Indiana Protein Technologies into a successful specialty pharmaceutical company and managed its acquisition by IVAX Corp (now part of Teva Pharmaceutical Industries Limited) in 2006. Ron spent a significant part of his career as Chief Scientist with Eli Lilly & Company for 28 years. He holds a Master of Science in Physiology & Biology and a Bachelor of Science in Physiology from Indiana State University. He is published in several peer-reviewed scientific publications and holds multiple patents in innovative production processes for both novel and bioequivalent protein products.

team member

David Wood

President & Chief Executive Officer

×

David Wood

President & Chief Executive Officer

David Wood brings 30+ years of expertise as a strategic and growth-oriented operations executive with a track record of building business, delivering revenue growth, and creating world-class operational structures to sustain growth and profitability. He has experience as President, COO, VP/General Manager and Board of Directors member for public and private companies. David served as Chief Restructuring Officer for Scient, Inc., a consulting company founded in 1997 where he had also served as VP/GM for the Enterprise Business Unit, building it to a $180 million business. Prior to that he was President & COO of an international consumer products company creating $400 million in shareholder value, validated by Credit Suisse First Boston during an expansion-financing round. Earlier in his career, David held various executive and operations roles with PepsiCo. Before entering the private sector, David was a Captain in the United States Army, Field Artillery. He holds a Bachelor of Science, Economics, Cum Laude, from Northeastern University.

team member

Dr. Donna Zimmerman

Vice President of Regulatory Affairs Nominee

×

Dr. Donna Zimmerman

Vice President of Regulatory Affairs Nominee

Dr. Zimmerman has 30+ years of experience at a senior level in the life sciences industry, in clinical and regulatory affairs, IND, NDA and regulatory submission, and clinical study management. Prior to co-founding ZBP, she was the CFO and Head of Clinical and Regulatory Affairs of Elona Biotechnologies, Inc. Dr. Zimmerman was also the Director, Clinical and Regulatory Affairs of Indian Protein Technologies, managing the financial aspects of the company until its acquisition by IVAX Corp (now part of Teva Pharmaceutical Industries Limited) in 2006. She founded and led a clinical trial management company, responsible for managing all aspects of clinical trials for multiple clients simultaneously. Dr. Zimmerman is a private pilot, holds a PhD in Health Research Administration from Kennedy Western University, a Master of Business Administration from Indiana Wesleyan University, a Bachelor of Science in Chemistry & Biology from the University of Indiana, and an Associate of Science in nursing from Colorado State University.

team member

Dr. Alexander Fleming

Chief Medical Officer Nominee

×

Dr. Alexander Fleming

Chief Medical Officer Nominee

Dr. Fleming received his M.D. in Internal Medicine training from Emory followed by fellowships at Vanderbilt and NIH. At the FDA, he led clinical reviews of biotech products including metformin, insulin analogs, statins, and human insulin. Dr. Fleming is also an author of multiple medical and scientific papers, and is a major contributor to FDA’s Good Review Practice (GRP) initiative.

Board of Advisors

Roger Harrison, PhD

Executive, Consultant

Robert L. Zied

Entrepreneur

David Wamsley

Finance Expert

Anthony Moravec

Entrepreneur

Rod Turner

Finance Expert


Global Diabetes Impact

460M Diabetics Worldwide*
1 in 10 Americans*
Of AllU.S. Deaths*

References

*Facts and figures regarding demand, sales, and cost of insulin are referenced from the Centers for Disease Control and Prevention (CDC) and the International Diabetes Federation.

Are You Ready to Save Lives?

Help us bring our affordable insulin to market with an investment today.

Comments

Post comment

Offering Circular

Please read the Offering Circular here: Get Offering Circular

THE COMPANY IS “TESTING THE WATERS” UNDER REGULATION A UNDER THE SECURITIES ACT OF 1933. THIS PROCESS ALLOWS COMPANIES TO DETERMINE WHETHER THERE MAY BE INTEREST IN AN EVENTUAL OFFERING OF ITS SECURITIES. THE COMPANY IS NOT UNDER ANY OBLIGATION TO MAKE AN OFFERING UNDER REGULATION A. IT MAY CHOOSE TO MAKE AN OFFERING TO SOME, BUT NOT ALL, OF THE PEOPLE WHO INDICATE AN INTEREST IN INVESTING, AND THAT OFFERING MIGHT NOT BE MADE UNDER REGULATION A. IF THE COMPANY DOES GO AHEAD WITH AN OFFERING, IT WILL ONLY BE ABLE TO MAKE SALES AFTER IT HAS FILED AN OFFERING STATEMENT WITH THE SECURITIES AND EXCHANGE COMMISSION (SEC) AND THE SEC HAS “QUALIFIED” THE OFFERING STATEMENT. THE INFORMATION IN THAT OFFERING STATEMENT WILL BE MORE COMPLETE THAN THE INFORMATION THE COMPANY IS PROVIDING NOW, AND COULD DIFFER IN IMPORTANT WAYS. YOU MUST READ THE DOCUMENTS FILED WITH THE SEC BEFORE INVESTING.

SEC REQUIREMENTS; MAKE SURE THIS INFORMATION HAS BEEN SEEN AND PREFERABLY AGREED TO PRIOR TO PERMITTING POTENTIAL INVESTOR TO INDICATE INTEREST:
NO MONEY OR OTHER CONSIDERATION IS BEING SOLICITED, AND IF SENT IN RESPONSE, WILL NOT BE ACCEPTED.
NO OFFER TO BUY THE SECURITIES CAN BE ACCEPTED AND NO PART OF THE PURCHASE PRICE CAN BE RECEIVED UNTIL THE OFFERING STATEMENT FILED BY THE COMPANY WITH THE SEC HAS BEEN QUALIFIED BY THE SEC. ANY SUCH OFFER MAY BE WITHDRAWN OR REVOKED, WITHOUT OBLIGATION OR COMMITMENT OF ANY KIND, AT ANY TIME BEFORE NOTICE OF ACCEPTANCE GIVEN AFTER THE DATE OF QUALIFICATION.
AN INDICATION OF INTEREST INVOLVES NO OBLIGATION OR COMMITMENT OF ANY KIND.

AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. YOU MAY OBTAIN A COPY OF THE PRELIMINARY OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT FROM:

https://www.manhattanstreetcapital.com/offering-circular/25008